GRAL grail.com: יחס שווי כולל של החברה להכנסות

לוגו של חברה ציבורית grail.com (GRAL)

The EV/Sales valuation level reflects the market perception of GRAIL, Inc. (GRAL), where 24075.69 serves as the current metric. This trend is supported by a team of top-tier AI engineers and biologists developing cutting-edge R&D solutions. However, the lack of stable cash flow due to marketing expenses creates risks. Future prospects depend on the expansion of the Galleri test and anticipated Medicare approval.

יחס שווי פעילות להכנסות: GRAIL Bio (GRAL) עבור 23.11.2025 - 20.11.2026

GRAIL Bio - פילוחים אנליטיים ומדדי מפתח (GRAL)

- מחיר שוק ויעדי מחיר של אנליסטים:
ניתוח ראשוני של החברה:GRAIL - GRAL
מוצר סדרתי של GRAIL Corp

GRAIL, Inc. (GRAL) is scaling cancer diagnostics through a single blood test, expanding patient reach. This indicator compares the total enterprise value of the business with its annual revenue, excluding the impact of debt obligations. Analyzing changes in the EV/Sales ratio allows for an assessment of the market value of one dollar of revenue regardless of debt load. This chart reflects investor perception of the efficiency of test commercialization. The final valuation requires adjustment for tax factors.